Insmed (INSM) Non-Current Debt (2012 - 2026)
Insmed's (INSM) quarterly Non-Current Debt came in at $546.8 million in Q1 2026, down 50.52% year-on-year from $1.1 billion in Q1 2025, and up 1.07% quarter-over-quarter from $541.0 million in Q4 2025.
Insmed (INSM) Non-Current Debt (2012 - 2026) Analysis & Trends
Insmed's Non-Current Debt history runs 15 years deep, the most recent figure standing at $546.8 million for Q1 2026.
- On a quarterly basis, Non-Current Debt fell 50.52% year-over-year to $546.8 million in Q1 2026; TTM through Mar 2026 was $546.8 million, a 50.52% decrease from a year earlier, with the FY2025 full-year figure at $541.0 million, down 50.97% from the prior year.
- Non-Current Debt advanced to $546.8 million in Q1 2026 per INSM's latest filing, from $541.0 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.2 billion in Q3 2023 and bottomed at $538.5 million in Q2 2025.
- The 5-year median for Non-Current Debt is $946.8 million (2024), against an average of $903.9 million.
- Across the five-year window, Non-Current Debt jumped 121.25% in 2022 and plunged 50.97% in 2025, its largest moves.
- Year by year, Non-Current Debt stood at $1.1 billion in 2022, then climbed by 2.67% to $1.2 billion in 2023, then dropped by 4.49% to $1.1 billion in 2024, then plunged by 50.97% to $541.0 million in 2025, then advanced by 1.07% to $546.8 million in 2026.
- Per Business Quant, the three latest INSM Non-Current Debt figures stand at $546.8 million (Q1 2026), $541.0 million (Q4 2025), and $539.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Insmed | 23.26 Bn | 22.03 Bn | 258.54 Mn | 546.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 546.77 Mn |
| Dec 31, 2025 | 540.96 Mn |
| Sep 30, 2025 | 539.72 Mn |
| Jun 30, 2025 | 538.51 Mn |
| Mar 31, 2025 | 1.11 Bn |
| Dec 31, 2024 | 1.10 Bn |
| Sep 30, 2024 | 971.76 Mn |
| Jun 30, 2024 | 946.83 Mn |
| Mar 31, 2024 | 939.08 Mn |
| Dec 31, 2023 | 1.16 Bn |
| Sep 30, 2023 | 1.17 Bn |
| Jun 30, 2023 | 1.17 Bn |
| Mar 31, 2023 | 1.13 Bn |
| Dec 31, 2022 | 1.13 Bn |
| Sep 30, 2022 | 784.80 Mn |
| Jun 30, 2022 | 800.00 Mn |
| Mar 31, 2022 | 800.00 Mn |
| Dec 31, 2021 | 566.59 Mn |
| Sep 30, 2021 | 557.60 Mn |
| Jun 30, 2021 | 548.75 Mn |